Abstract
The aggregation of beta-amyloid (Aβ) into plaques in the extracellular compartment of the brain is a pathological hallmark of Alzheimer’ s disease (AD). Although the pathways for misprocessing of Aβ leading to plaque formation are not well understood, they may be related to synapse turnover and neuron activity. In this study, we have utilised transgenic mice co-expressing mutations in the amyloid precursor protein and presenilin 1 genes (APP/PS1) to determine how long-term denervation of the olfactory bulb, a CNS area affected early by AD-like pathology, may affect Aβ plaque formation. The olfactory bulb of pre-symptomatic mice was denervated by ablating the olfactory epithelium unilaterally with Triton X-100 solution. Mice were subjected to nasal washes for a total of 4 or 8 times, at 3-week intervals either with 1% Triton X-100 solution or phosphate buffered saline (sham denervation). Denervation of the olfactory bulb resulted in a statistically significant (p<0.05) decrease in amyloid plaque load in the ipsilateral olfactory bulb, and bilaterally also in the neocortex and hippocampus at 8-9 months age. Amyloid precursor protein was predominantly expressed by mitral cells in the olfactory bulb, which are normally postsynaptic to olfactory axons. The number of APP positive mitral cells was significantly increased in the denervated olfactory bulb of wild type but not of the APP/PS1 mice, which consistently showed high immunoreactivity for APP pre- and post-denervation. In summary, our results show that Aβ plaque deposition in the central nervous system can be modified transsynaptically by deafferentation.
Keywords: Alzheimer’ s disease, amyloid plaque load, amyloid precursor protein, denervation, olfactory bulb.
Current Alzheimer Research
Title:Denervation of the Olfactory Bulb Leads to Decreased Aβ Plaque Load in a Transgenic Mouse Model of Alzheimer’ s Disease
Volume: 10 Issue: 7
Author(s): OIivier Bibari, Siak Lee, Tracey C. Dickson, Stan Mitew, James C. Vickers and Meng I. Chuah
Affiliation:
Keywords: Alzheimer’ s disease, amyloid plaque load, amyloid precursor protein, denervation, olfactory bulb.
Abstract: The aggregation of beta-amyloid (Aβ) into plaques in the extracellular compartment of the brain is a pathological hallmark of Alzheimer’ s disease (AD). Although the pathways for misprocessing of Aβ leading to plaque formation are not well understood, they may be related to synapse turnover and neuron activity. In this study, we have utilised transgenic mice co-expressing mutations in the amyloid precursor protein and presenilin 1 genes (APP/PS1) to determine how long-term denervation of the olfactory bulb, a CNS area affected early by AD-like pathology, may affect Aβ plaque formation. The olfactory bulb of pre-symptomatic mice was denervated by ablating the olfactory epithelium unilaterally with Triton X-100 solution. Mice were subjected to nasal washes for a total of 4 or 8 times, at 3-week intervals either with 1% Triton X-100 solution or phosphate buffered saline (sham denervation). Denervation of the olfactory bulb resulted in a statistically significant (p<0.05) decrease in amyloid plaque load in the ipsilateral olfactory bulb, and bilaterally also in the neocortex and hippocampus at 8-9 months age. Amyloid precursor protein was predominantly expressed by mitral cells in the olfactory bulb, which are normally postsynaptic to olfactory axons. The number of APP positive mitral cells was significantly increased in the denervated olfactory bulb of wild type but not of the APP/PS1 mice, which consistently showed high immunoreactivity for APP pre- and post-denervation. In summary, our results show that Aβ plaque deposition in the central nervous system can be modified transsynaptically by deafferentation.
Export Options
About this article
Cite this article as:
Bibari OIivier, Lee Siak, Dickson C. Tracey, Mitew Stan, Vickers C. James and Chuah I. Meng, Denervation of the Olfactory Bulb Leads to Decreased Aβ Plaque Load in a Transgenic Mouse Model of Alzheimer’ s Disease, Current Alzheimer Research 2013; 10 (7) . https://dx.doi.org/10.2174/15672050113109990147
DOI https://dx.doi.org/10.2174/15672050113109990147 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot Topic:Applications of Angiotensin Converting Enzyme Inhibitors and of Angiotensin II Receptor Blockers in Pharmacology and Therapy: An Update (Executive Editor: Agostino Molteni)]
Current Pharmaceutical Design Neuroprotective Effects of Quercetin: From Chemistry to Medicine
CNS & Neurological Disorders - Drug Targets A Review on Novel Ligand Targeted Delivery for Cardiovascular Disorder
Current Drug Delivery Pyrrolo-isoxazole: A Key Molecule with Diverse Biological Actions
Mini-Reviews in Medicinal Chemistry Meet Our Editorial Board
Current Alzheimer Research Editorial [Hot topic: Parkinsons Disease (Guest Editor: Jurgen Dinges)]
Current Topics in Medicinal Chemistry Chronic Alcohol Abuse and HIV Disease Progression: Studies with the Non-Human Primate Model
Current HIV Research Serum Testosterone and Cognitive Function in Ageing Male: Updating the Evidence
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Role of Neuronal Insulin/Insulin-Like Growth Factor-1 Signaling for the Pathogenesis of Alzheimer’s Disease: Possible Therapeutic Implications
CNS & Neurological Disorders - Drug Targets Potential Benefits and Limits of Psychopharmacological Therapies in Pervasive Developmental Disorders
Current Clinical Pharmacology Evaluation of Blood Pressure Control using a New Arterial Stiffness Parameter, Cardio-ankle Vascular Index (CAVI)
Current Hypertension Reviews Mitochondrial Metabolism Modulation: A New Therapeutic Approach for Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Relationship Between Hypertension and Atherosclerosis: From a Viewpoint of the Most Potent Vasoconstrictor Human Urotensin II
Current Hypertension Reviews Potential New Targets for Antithrombotic Therapy
Current Pharmaceutical Design Silymarin Extends Lifespan and Reduces Proteotoxicity in C. elegans Alzheimer’s Model
CNS & Neurological Disorders - Drug Targets The Novel Role for Lyn in Integrin Signaling in Human Disease
Current Signal Transduction Therapy Short- and Long-Term Survival of Nonsurgical Intensive Care Patients and its Relation to Diagnosis, Severity of Disease, Age and Comorbidities
Current Aging Science Virus Vasculopathy and Stroke: An Under-Recognized Cause and Treatment Target
Infectious Disorders - Drug Targets Neurogenesis and Alzheimers Disease: Biology and Pathophysiology in Mice and Men
Current Alzheimer Research Editorial: Speech Production in Persons with Dementia
Current Alzheimer Research